On April 7, Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) again raised the limit to close at 38.16 yuan. The share price hit a record high, with a turnover of 6.686 billion yuan and a turnover rate of 13.27%. The stock rose more than 94% during the year.
According to the after hours dragon and tiger list data, Shenzhen Stock connect bought 241 million yuan of special seats and sold 185 million yuan, a net purchase of 109 million yuan of special seats for institutions and a net sale of 547697 million yuan of special seats for institutions.
Recently, traditional Chinese medicine stocks continued to strengthen, and individual stocks rose in a large area. In terms of news, according to Xinhua news agency, the WHO website recently released the report of the WHO expert evaluation meeting on the treatment of covid-19 pneumonia with traditional Chinese medicine, which clearly affirmed the safety and effectiveness of traditional Chinese medicine in the treatment of covid-19 pneumonia.
The World Health Organization pointed out in the report that traditional Chinese medicine can effectively treat covid-19 pneumonia and reduce the conversion of light and common cases to severe cases; For mild and common cases, compared with simple routine treatment, traditional Chinese medicine as an additional intervention can shorten the virus clearance time, clinical symptom relief time and hospital stay.
Citic Securities Company Limited(600030) said that in terms of China’s policies, the recent release of the 14th five year plan for the development of traditional Chinese medicine has provided positive policy guidance for the development of the industry. The Chinese medicine sector is expected to usher in a dilemma reversal in 2022. The Chinese medicine market is sustainable in the medium and long term. In the short term, we can pay attention to structural opportunities. In the medium and long term, we can pay attention to the target enterprises that benefit from policy promotion, innovation and R & D and consumption upgrading.
